Clinical Trials Logo

Clinical Trial Summary

Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).


Clinical Trial Description

The investigators will use a randomized, placebo-controlled, double-blind, crossover trial to evaluate the use of fMRI as a pharmacodynamic biomarker of reward system modulation. The overall goal of this work is to develop an objective tool to detect acute drug response. If validated in future, larger trials, the pharmacodynamic biomarker may facilitate early phase/quantitative pharmacology studies of novel or repurposed agents expected to modulate the reward system. The reward system will be antagonized by naltrexone in adolescents aged 13-21 years with an ED defined by binge/purge behaviors (e.g., Anorexia Nervosa-Binge Purge, Bulimia Nervosa, Binge Eating Disorder). A crossover design was chosen to quantify within-individual change in opioid reward pathway modulation following antagonism. Eligible patients will be randomly assigned to Group A or Group B. A statistician (or other non-study staff) will generate the schedule and communicate with the investigation drug service to maintain the double-blind design. A washout period of at least 14 days will exceed the 48-hour carry-over effect from naltrexone 50 mg administered orally. The two study visits will be mirrored in structure and duration to maintain blinding. It is not the intent of this study to generate data for submission to the FDA or to support a significant change in advertising of the drug. Storage, control and dispensation of the drug will occur through collaboration with the investigational drug service (IDS) pharmacy. Use of naltrexone for this study meets criteria for investigational new drug (IND) exemption, category #1 (21 Code of Federal Regulations (CFR) 312.2(b)(1)). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05509257
Study type Interventional
Source Children's Mercy Hospital Kansas City
Contact John Tumberger, BS
Phone 8164829872
Email jtumberger@cmh.edu
Status Recruiting
Phase Early Phase 1
Start date September 17, 2022
Completion date June 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05656859 - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed NCT04085861 - Mental Health in Dancers; an Intervention Study N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT03050632 - Effects of Cognitive and Emotional Functioning on Treatment Outcomes N/A
Completed NCT02567890 - Swedish Body Project for Prevention of Eating Disorders N/A
Completed NCT02484794 - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application N/A
Completed NCT02252822 - Improving Treatment Engagement for Adolescents With Bulimia Nervosa N/A
Completed NCT02021344 - Mental Health First Aid for College Students N/A
Completed NCT00601354 - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder N/A
Completed NCT00418977 - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents N/A
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Completed NCT00733525 - Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa N/A
Active, not recruiting NCT04779216 - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa Phase 3
Completed NCT04433663 - Eating Disorders, Self Regulation and Mentalization N/A
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT05730348 - Mealtime Anxiety in Eating Disorders
Enrolling by invitation NCT05814653 - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders N/A
Completed NCT04506216 - Eating Disorders in Type 1 Insulin-dependent Diabetes Patients N/A